Zika Virus Infection: Key Facts You Should Know

Ten years after Zika virus was declared a Public Health Emergency of International Concern, the world's relationship with this pathogen has fundamentally changed - but the threat has not disappeared. The explosive outbreaks that swept across Brazil and the Americas between 2015 and 2016, leaving thousands of infants born with severe brain damage, triggered one of the most intensive global public health mobilizations since the AIDS crisis. Cases declined sharply after that peak. But the virus never left.

A May 2026 WHO epidemiology update confirmed that there is now evidence of current or previous autochthonous Zika virus transmission in 97 countries and territories globally. As of March 10, 2026, PAHO and WHO reported 7,654 suspected and 551 confirmed Zika cases in the Americas alone for 2026. In 2025, over 25,800 suspected cases were reported in the region. Projections suggest that over 1.3 billion people could face conditions favorable for Zika transmission by 2050 as climate change expands the geographic range of Aedes mosquitoes.

For travelers, pregnant women, their partners, and anyone seeking to understand one of the defining infectious disease events of the 21st century, a clear and factual understanding of Zika virus is essential. This article covers the biology, transmission, symptoms, risks - particularly for pregnancy - diagnosis, treatment, prevention, and the current state of vaccine development.

What Is Zika Virus?

Origins and Classification

Zika virus (ZIKV) is a single-stranded RNA virus of the Flaviviridae family, genus Flavivirus - the same family that includes dengue, yellow fever, Japanese encephalitis, and West Nile virus. It was first isolated in 1947 from a febrile rhesus macaque in the Zika Forest of Uganda, and the first confirmed human infection was documented in 1954 in Africa. For decades it remained a largely obscure pathogen causing only sporadic infections. Then, beginning with an outbreak in the Yap Islands in 2007 and escalating through French Polynesia in 2013, it entered the Americas and transformed from an obscure tropical curiosity into a global health emergency.

Two lineages of Zika virus are recognized: the African lineage and the Asian lineage, both of which have spread in the Americas. The Asian lineage was responsible for the 2015 to 2016 outbreak in Brazil and the vast majority of documented cases of congenital Zika syndrome.

The Mosquito Vector

Zika is transmitted primarily through the bite of infected Aedes species mosquitoes - most commonly Aedes aegypti, the same species that transmits dengue, chikungunya, and yellow fever, and to a lesser extent Aedes albopictus (the Asian tiger mosquito). These mosquitoes are aggressive daytime biters, typically most active in the hours after sunrise and before sunset, though they continue biting into evening hours. They thrive in urban and suburban environments, breed in small standing water containers (flower pots, discarded tires, water storage containers), and are found throughout tropical and subtropical regions of the world.

The geographic range of Aedes aegypti is expanding due to climate change, raising concern about Zika reaching new territories. The virus has been detected in an ever-broader geographic footprint - with recent clusters reported in India (2022 and 2023), Singapore (2023), Thailand (2023), and Papua New Guinea in addition to the established endemic areas across the Americas, Southeast Asia, and the Pacific islands.

How Zika Spreads: Multiple Transmission Routes

Primary Route: Mosquito Bite

The dominant route of transmission is the bite of an infected Aedes mosquito. A mosquito becomes infected by biting a person already carrying the virus, incubates the virus within its own tissues (the extrinsic incubation period), and then transmits it to the next person it bites. Standard insect repellent use, protective clothing, and mosquito control measures interrupt this transmission cycle.

Sexual Transmission: A Clinically Important Route

Zika is the first mosquito-borne virus documented to spread through sexual contact. The virus can persist in semen for weeks to months after infection - including in people who were asymptomatic and never knew they were infected. It has been detected in vaginal secretions as well. Transmission has been documented through vaginal, anal, and oral sex. Studies suggest Zika can spread through sex for up to six weeks after symptoms begin, and the CDC recommends using condoms during this period for anyone who may have been exposed.

This sexual transmission route is particularly clinically relevant for pregnant women and their partners: if a male partner has traveled to an area with Zika transmission, condom use or abstinence is recommended for the remainder of the pregnancy, because the risk of congenital Zika syndrome from sexual transmission is equivalent to the risk from mosquito bite transmission.

Mother-to-Fetus Transmission

Zika virus can cross the placental barrier and infect the developing fetus throughout pregnancy. Vertical transmission from mother to fetus - particularly during the first trimester when neural development is most active - is the mechanism by which congenital Zika syndrome occurs. The virus has also been detected in breast milk, though transmission through breastfeeding has not been confirmed.

Blood Transfusion

Health officials have reported Zika transmission through blood transfusions in Brazil and France. Blood supply screening for Zika has been implemented in several countries, including the United States, to prevent this route of transmission.

Laboratory Transmission

One confirmed case of laboratory-acquired Zika infection has been documented, illustrating that laboratory workers handling the virus require appropriate biosafety precautions.

Symptoms: What Zika Feels Like in Most People

Typically Mild or Asymptomatic

One of the most epidemiologically significant features of Zika is that approximately 80% of infected individuals have no symptoms at all. The majority of people infected with Zika never know they have it. This large pool of asymptomatic carriers is a major driver of ongoing silent transmission - both by mosquito and through sexual contact.

When symptoms do occur, they are generally mild and self-limiting, lasting two to seven days. The classic clinical presentation includes:

• Maculopapular rash - a flat, red rash often starting on the face and spreading to the body, affecting the palms and soles; this is one of the most consistent findings in symptomatic infection
• Low-grade fever - typically below 38.5°C (101.3°F), milder than dengue or chikungunya fevers
• Joint pain (arthralgia) - affecting the small joints of the hands and feet, sometimes with swelling; can be quite uncomfortable
• Non-purulent conjunctivitis - redness of the eyes (often called "pink eye") without discharge, distinguishing it from bacterial conjunctivitis

Additional symptoms documented in the CDC Yellow Book 2026 edition include headache, lymphadenopathy (swollen lymph nodes), myalgia (muscle pain), retro-orbital pain (pain behind the eyes), edema, and vomiting. Death and severe disease requiring hospitalization are uncommon in otherwise healthy adults.

How to Distinguish Zika From Dengue and Chikungunya

Because all three viruses are transmitted by Aedes aegypti mosquitoes and overlap geographically, clinical distinction is important and often challenging. Dengue typically presents with more severe fever, significant muscle and bone pain ("breakbone fever"), potential hemorrhagic manifestations, and a higher rate of serious illness. Chikungunya is characterized by extremely severe joint pain that can persist for months or years. Zika's relatively milder fever and the presence of conjunctivitis and a more pronounced rash help distinguish it, but laboratory testing is often required for definitive differentiation - particularly relevant because the CDC recommends against aspirin and NSAIDs until dengue is ruled out, due to bleeding risk.

The High-Stakes Risk: Zika in Pregnancy

Congenital Zika Syndrome

While most adults infected with Zika experience only mild or no illness, the same virus causes catastrophic consequences when a fetus is infected. Zika virus infection during pregnancy can result in congenital Zika virus infection with a constellation of severe outcomes.

Approximately 5% (1 in 20) of babies born to someone infected with Zika during pregnancy have congenital conditions, including:

• Microcephaly - a significantly smaller-than-average head circumference, resulting from impaired brain development. In Brazil, infant microcephaly rates increased approximately 20-fold at the peak of the 2015 to 2016 outbreak - a signal so alarming it triggered the PHEIC declaration
• Brain abnormalities - including intracranial calcifications, cortical malformations, ventriculomegaly, and abnormal brain folding patterns (polymicrogyria, pachygyria, lissencephaly)
• Eye abnormalities - retinal lesions, optic nerve hypoplasia, chorioretinal atrophy, and foveal abnormalities causing visual impairment
• Hearing impairment
• Joint abnormalities - including arthrogryposis (joint contractures)
• Impaired growth - fetal growth restriction

The full clinical constellation - severe microcephaly, partially collapsed skull, reduced brain tissue, eye damage, joint issues, and hypertonia - constitutes congenital Zika syndrome. The consequences for affected children are severe: intellectual disability, developmental delays, seizures, vision and hearing problems, and shortened life expectancy.

When During Pregnancy Is the Risk Highest?

Infection during the first trimester carries the highest risk of severe congenital anomalies because this is the critical window for neural tube formation, cortical development, and brain structure assembly. However, serious complications have been documented from infections in all trimesters. The virus's ability to preferentially infect neural progenitor cells - the stem cells that generate the brain's cortical neurons - is the mechanism by which it disrupts brain development with such devastating consequences.

Even in the absence of microcephaly at birth, infants exposed to Zika in utero may experience neurodevelopmental deficits including developmental delays, abnormal muscle tone, seizures, and feeding difficulties - a broader spectrum of neurodevelopmental impact that researchers are still characterizing.

Pregnancy Monitoring and Management

Pregnant women who test positive for Zika or who were exposed during travel to an endemic area should be closely monitored throughout pregnancy. Ultrasound monitoring for signs of microcephaly or brain abnormalities is the primary surveillance tool, though even advanced imaging cannot rule out all Zika-related effects. Amniocentesis for viral RNA testing may be offered in high-risk cases.

Critically, no clinician can predict or prevent pregnancy complications once infection has occurred. Prevention of infection - by avoiding travel to endemic areas during pregnancy, using mosquito repellent and protective clothing rigorously when travel is unavoidable, and ensuring partners use condoms - remains the only effective protective strategy.

Neurological Complications in Adults: Guillain-Barré Syndrome

Zika is not only a threat to fetuses. In adults, the most significant complication is Guillain-Barré syndrome (GBS) - an autoimmune disorder in which the immune system attacks the peripheral nervous system, producing progressive muscle weakness and, in severe cases, paralysis. Approximately 2 in 10,000 people infected with Zika develop GBS, a rate that is significantly elevated compared to background rates in the population.

The association between Zika and GBS was first recognized during the 2013 to 2014 French Polynesian outbreak, where 24 cases of GBS occurred in a community of only 270,000 people over a few months - a cluster that prompted intensive epidemiological investigation. Brazil's 2015 to 2016 outbreak produced further data confirming the causal link.

Most people recover from GBS within weeks to months with appropriate supportive care. Treatment for Zika-associated GBS includes plasmapheresis (plasma exchange) or intravenous immunoglobulin (IVIG) to modulate the autoimmune response, along with intensive rehabilitation. A small proportion of GBS cases progress to respiratory failure requiring mechanical ventilation, and the disease can rarely be fatal.

The CDC Yellow Book 2026 also documents rare reports of encephalopathy, meningoencephalitis, myelitis, uveitis (eye inflammation), and severe thrombocytopenia (dangerously low platelet counts) associated with Zika infection - though these remain unusual complications.

Diagnosis: How Zika Is Confirmed

The Diagnostic Challenge

Diagnosing Zika presents several technical challenges. The virus' cross-reactivity with related flaviviruses - particularly dengue - means that antibody tests (serology) can produce false positives in individuals previously infected with or vaccinated against related flaviviruses. This cross-reactivity makes antibody-based diagnosis unreliable in populations with high dengue prevalence.

Since 2019, the CDC notes that all locally acquired Zika cases in US territories have been diagnosed by antibody testing, but acknowledges this cannot distinguish recent from past infection, or Zika from dengue antibodies. This diagnostic limitation significantly affects the accuracy of case counts.

Recommended Testing Approach

The CDC Yellow Book 2026 recommends considering Zika in patients with acute onset of fever, arthralgia, conjunctivitis, or maculopapular rash who, within two weeks of illness onset, lived in or recently traveled to areas with current or past Zika transmission.

The preferred diagnostic approaches are:

• Real-time PCR for viral RNA - the most sensitive and specific test during the acute phase (within the first 1 to 2 weeks of symptom onset), detecting viral RNA directly in blood, urine, or saliva. The CDC notes that urine samples may remain positive longer than blood
• NS1 antigen test - an emerging diagnostic tool that detects Zika virus NS1 protein, potentially offering a faster and less cross-reactive alternative to antibody testing
• Serology (IgM antibody testing) - useful later in the course of illness when viral RNA may no longer be detectable, but subject to the cross-reactivity issues described above
• Plaque reduction neutralization test (PRNT) - the most specific antibody test, used to confirm equivocal serology results; available at specialized public health laboratories

Prenatal diagnosis may involve amniocentesis for viral RNA testing, though results require expert interpretation in context.

Treatment: What Medicine Can and Cannot Do

No Approved Antivirals or Vaccines

This is the most important clinical fact about Zika treatment: there is no specific antiviral medication approved for Zika virus infection, and no licensed vaccine exists. Despite an intensive global research effort triggered by the 2015 to 2016 outbreak, Zika joins a long list of flaviviruses - including dengue, chikungunya, and West Nile - for which no approved antiviral drugs are available.

Supportive Care for Acute Illness

For most healthy adults, Zika infection resolves without medical intervention. The management of acute symptomatic illness is entirely supportive:

• Adequate rest and hydration
• Acetaminophen (paracetamol) for fever and pain relief
• Avoidance of aspirin and NSAIDs (ibuprofen, naproxen) until dengue is definitively ruled out, due to the risk of hemorrhagic complications in dengue
• Mosquito avoidance during the acute illness period to prevent transmitting the virus to biting mosquitoes that could then spread it to others

Management of Serious Complications

For GBS, medical management includes IVIG or plasmapheresis as immune-modulating therapies, intensive supportive care including respiratory monitoring, and physical rehabilitation. For congenital Zika syndrome, management focuses on supportive care and addressing specific developmental needs: seizure management, physical and occupational therapy, ophthalmological and audiological care, developmental support, and family counseling.

The Vaccine Development Pipeline

The absence of a licensed vaccine is not for lack of scientific effort. Multiple vaccine platforms have entered clinical trials since 2016, including purified inactivated virus vaccines, DNA vaccines, mRNA vaccines (which leveraged the same platform success seen with COVID-19), live-attenuated vaccines, and viral-vectored vaccines.

A DNA vaccine developed by the NIH advanced rapidly into Phase I trials and demonstrated immunogenicity, and a 2025 Nature Communications paper described rational design of a Zika flavivirus E protein vaccine that optimizes immunogenicity while mitigating antibody-dependent enhancement risk - a key safety concern given dengue cross-reactivity. However, no Zika vaccine has yet completed Phase III efficacy trials or received regulatory approval. The decline in Zika transmission after the 2016 peak has made conducting large-scale efficacy trials difficult - an ironic consequence of successful outbreak control.

The 2025 WHO Global Strategic Preparedness, Readiness, and Response Plan specifically prioritizes Zika vaccine development as a key objective, recognizing that the next outbreak will demand a ready countermeasure.

Prevention: How to Protect Yourself

Mosquito Bite Prevention

Since the primary route of Zika transmission is mosquito bite, bite prevention is the foundation of protection. Evidence-based mosquito repellent approaches recommended by CDC include:

• DEET (diethyltoluamide) - the most extensively tested repellent, effective at concentrations of 20 to 50%; safe for use in pregnant women
• Picaridin - a synthetic alternative to DEET, equally effective, with better skin feel and less odor
• IR3535 - another synthetic repellent with good efficacy against Aedes mosquitoes
• Oil of lemon eucalyptus - the only plant-based repellent recommended by CDC for adults; not for use in children under 3
• Permethrin - an insecticide applied to clothing and gear (not skin), providing additional protection; kills mosquitoes on contact; safe for pregnant women when used on fabric

Protective clothing complements repellent use: long sleeves, long pants, and closed-toe shoes reduce exposed skin surface available for biting. In endemic areas, air conditioning and window and door screens keep mosquitoes out of indoor environments.

Sexual Transmission Prevention

For individuals who have been in areas with Zika risk:

• Use condoms or abstain from sex for at least eight weeks after returning from an area with Zika, regardless of whether symptoms developed
• For pregnant women with partners who traveled to Zika areas, condom use is recommended for the entire duration of the pregnancy
• Men with Zika infection confirmed by testing should use condoms for at least six months after symptom onset (the upper estimated limit of viral shedding in semen)
• Women with confirmed Zika should wait at least eight weeks before attempting to conceive

Travel Precautions

The CDC advises pregnant women to avoid travel to areas with Zika transmission if at all possible. For those who must travel, rigorous mosquito bite prevention throughout the trip is essential. As of 2026, Puerto Rico remains categorized as having a risk of Zika transmission due to Aedes aegypti mosquitoes.

For travelers returning from endemic areas who develop fever, rash, joint pain, or conjunctivitis within two weeks of return, Zika should be included in the differential diagnosis and testing requested. In the US, both public health and commercial laboratory testing services can detect Zika infections.

Vector Control and Environmental Measures

Community-level prevention involves reducing breeding sites for Aedes mosquitoes - emptying and scrubbing water-holding containers weekly, covering water storage vessels, and properly disposing of items that hold water. Novel vector control approaches under investigation include the release of Wolbachia-infected mosquitoes that suppress dengue and Zika transmission, and genetically modified male mosquito release programs that reduce wild Aedes aegypti populations.

The Current Situation: Where Things Stand in 2026

Global Epidemiology

Ten years after the PHEIC declaration, Zika continues to circulate at lower endemic levels across 97 countries and territories. The dramatic decline from outbreak levels reflects a combination of factors: population immunity in previously exposed communities, sustained vector control efforts, and the epidemiological dynamics of flavivirus transmission in populations with significant prior immunity.

However, as the WHO's 2026 update emphasizes, the absence of a licensed vaccine means that large new outbreaks remain possible, particularly in naive populations or as Aedes mosquitoes expand their range into new territories.

Zika in the United States

The CDC reports data current as of June 2, 2026: the vast majority of Zika cases in the continental United States are travel-associated. In 2025, six travel-associated cases were documented and one locally acquired case. In 2024, the CDC recorded 19 non-congenital Zika cases among US residents, primarily travel-related. Puerto Rico continues to experience local transmission.

Since 2019, there have been no confirmed Zika virus disease cases reported from US territories that meet the current case definition - though the diagnostic limitations noted above mean the true picture is uncertain.

The 2050 Projection: A Long-Term Challenge

Projections suggest that over 1.3 billion people could live in conditions favorable for Zika transmission by 2050 as climate change expands the thermal and geographic range of Aedes aegypti northward and to higher elevations. This long-term trajectory reinforces the urgency of vaccine development, vector control innovation, and sustained surveillance systems.

What Travelers and Pregnant Women Should Do Right Now

For Travelers to Endemic Areas

• Check the CDC Zika travel notices before any international travel
• Use EPA-registered insect repellent containing DEET, picaridin, or IR3535 consistently
• Wear protective clothing and use window screens or air conditioning
• Use condoms for at least eight weeks after returning, regardless of symptoms
• See a healthcare provider promptly if you develop fever, rash, joint pain, or conjunctivitis within two weeks of return and inform them of your travel history

For Pregnant Women and Those Planning Pregnancy

• Avoid travel to areas with Zika transmission if at all possible during pregnancy
• If travel is unavoidable, use strict mosquito bite prevention measures throughout the trip
• Ensure male partners who have traveled to Zika-risk areas use condoms for the entire pregnancy
• Discuss Zika testing with your obstetrician if you or your partner may have been exposed
• Wait at least two months after potential Zika exposure before attempting to conceive (women) or eight weeks (men)

For Healthcare Providers

Consider Zika in the differential diagnosis of any patient with fever, arthralgia, conjunctivitis, or rash who traveled to an endemic area within two weeks of illness onset. Request PCR testing for viral RNA in blood and urine during the acute phase, and report confirmed or suspected cases to local public health authorities in accordance with mandatory reporting requirements.

Conclusion: Vigilance Without Panic

Zika virus is a pathogen that demands nuanced understanding. For most healthy, non-pregnant adults, infection is mild, self-limiting, and often unnoticed. The danger of Zika is not to those individuals - it is to the fetuses developing inside pregnant women who encounter this virus, and to the rare adult who develops Guillain-Barré syndrome.

Ten years of intensive global research have produced a thorough understanding of Zika's biology, transmission, and pathology - and have still not yielded a licensed vaccine or approved treatment. That gap, combined with the expanding geographic range of its mosquito vector, means that Zika remains an active and evolving public health challenge. The tools available to individuals - repellent, protective clothing, condoms, travel precautions, and timely testing - are effective at the individual level. The larger work of vector control, surveillance, and vaccine development requires the sustained investment and international cooperation that the disease's burden on vulnerable populations demands.

This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider or travel medicine specialist before traveling to areas with Zika transmission, and contact your obstetrician promptly if you are pregnant and have been potentially exposed.